SCYX-6759, the first member of a new class of anti-trypanosomal drugs, was discovered by a collaboration of DNDi, Anacor, PACE University and Scynexis. It was found that it achieved 100% efficacy in a murine stage 2 human African trypanosiomiasis (HAT) model (using Trypanosoma brucei), that it readily crossed the blood-brain and blood-testicular barriers, and that its efficacy could be predicted from brain exposure. Research on SCYX-6759 led to the development of SCYX-7158, a pre-clinical candidate for HAT treatment.
Presentation from American Society of Tropical Medicine and Hygiene 58th Annual Meeting, Washington, DC, USA, 18-22 November 2009.
SCYX-6759, an Orally Bioavailable Oxaborole 6-carboxamide, Achieves Therapeutically Relevant Exposure in Brain and CSF Leading to 100% Cures in a Mouse Model of CNS-stage Human African Trypanosomiasis.